Equities

AIM ImmunoTech Inc

AIM ImmunoTech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.20
  • Today's Change0.017 / 9.29%
  • Shares traded224.00
  • 1 Year change-51.69%
  • Beta-0.3717
Data delayed at least 15 minutes, as of Nov 21 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for AIM ImmunoTech Inc have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 1.00. The median estimate represents a 1,650.00% increase from the last price of 0.20.
High2,400.0%5.00
Med1,650.0%3.50
Low400.0%1.00

Earnings history & estimates in USD

On Nov 14, 2024, AIM ImmunoTech Inc reported 3rd quarter 2024 losses of -0.064 per share. This result exceeded the -0.10 consensus loss of the 2 analysts covering the company and exceeded last year's 3rd quarter results by 60.00%.
Average growth rate-0.50%
AIM ImmunoTech Inc reported annual 2023 losses of -0.600 per share on Apr 01, 2024.
Average growth rate+10.98%
More ▼

Revenue history & estimates in USD

AIM ImmunoTech Inc. had 3rd quarter 2024 revenues of 35.00k. This bettered the 18.00k consensus of the 2 analysts covering the company. This was 28.57% below the prior year's 3rd quarter results.
Average growth rate-0.54%
AIM ImmunoTech Inc. had revenues for the full year 2023 of 202.00k. This was 43.26% above the prior year's results.
Average growth rate+11.74%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.